Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis.

John, Binu V; Dahman, Bassam; Deng, Yangyang; Khakoo, Nidah S; Taddei, Tamar H; Kaplan, David E; Levy, Cynthia

John, Binu V; Dahman, Bassam; Deng, Yangyang; Khakoo, Nidah S; Taddei, Tamar H; Kaplan, David E; Levy, Cynthia.

Afiliação

John BV; Division of Hepatology, Bruce W Carter VA Medical Center, Miami, Florida, USA.
Dahman B; Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Deng Y; Department of Health Behavior and Policy, Virginia Commonwealth University, Richmond, Virginia, USA.
Khakoo NS; Department of Health Behavior and Policy, Virginia Commonwealth University, Richmond, Virginia, USA.
Taddei TH; Department of Medicine, Jackson Memorial Hospital, Miami, Florida, USA.
Kaplan DE; Section of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
Levy C; VA Connecticut Healthcare System, West Haven, Connecticut, USA.

Liver Int ; 42(2): 384-393, 2022 02.

Article em En | MEDLINE | ID: mdl-34614294

Assuntos

Carcinoma Hepatocelular; Colangite; Cirrose Hepática Biliar; Neoplasias Hepáticas; Autoanticorpos; Carcinoma Hepatocelular/complicações; Colangite/complicações; Humanos; Neoplasias Hepáticas/complicações; Masculino

Palavras-chave

antimitochondrial antibodies; autoimmune liver disease; cholestatic liver disease; decompensation; hepatocellular carcinoma; primary biliary cholangitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colangite / Carcinoma Hepatocelular / Cirrose Hepática Biliar / Neoplasias Hepáticas Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google